Kalaris Therapeutics Past Earnings Performance

Past criteria checks 0/6

Kalaris Therapeutics's earnings have been declining at an average annual rate of -27.5%, while the Biotechs industry saw earnings growing at 36.2% annually.

Key information

-27.50%

Earnings growth rate

5.77%

EPS growth rate

Biotechs Industry Growth	17.04%
Revenue growth rate	n/a
Return on equity	-64.32%
Net Margin	n/a
Last Earnings Update	31 Mar 2026

Recent past performance updates

No updates

Recent updates

Seeking Alpha • Dec 18

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth

Summary Kalaris Therapeutics, Inc. raised $50M post-positive TH103 trial data, strengthening its cash position to fund TH103 clinical development. KLRS reported improved Q3 '25 results, with a net loss of $11.9M and $77M in cash, supporting operations through 2027. TH103, KLRS’s lead asset, showed rapid efficacy and strong safety in Phase 1a, with further Phase 1b/2 data expected in H2 '26. KLRS stock's valuation is driven by TH103’s clinical potential, with an enterprise value of ~$119M and significant upside tied to trial catalysts. Read the full article on Seeking Alpha

Analysis Article • Nov 20

Kalaris Therapeutics (NASDAQ:KLRS) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Analysis Article • Jun 23

We're Hopeful That Kalaris Therapeutics (NASDAQ:KLRS) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Revenue & Expenses Breakdown

How Kalaris Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGM:KLRS Revenue, expenses and earnings (USD Millions)
Date	Earnings	G+A Expenses	R&D Expenses
31 Mar 26	-44	15	32
31 Dec 25	-43	15	31
30 Sep 25	-55	15	27
30 Jun 25	-82	13	54
31 Mar 25	-76	10	49
31 Dec 24	-69	7	45
30 Sep 24	-51	4	44
31 Dec 23	-15	2	12

Quality Earnings: KLRS is currently unprofitable.

Growing Profit Margin: KLRS is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KLRS is unprofitable, and losses have increased over the past 5 years at a rate of 27.5% per year.

Accelerating Growth: Unable to compare KLRS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: KLRS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: KLRS has a negative Return on Equity (-64.32%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/03 07:28
End of Day Share Price	2026/06/03 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kalaris Therapeutics, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Daniil Gataulin	Chardan Capital Markets, LLC
Jonathan Wolleben	Citizens JMP Securities, LLC
Marc Goodman	Leerink Partners LLC